The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology.
At the WCLC conference, ” Oncology Frontier” invited Dr. Han Baohui, Zhong Runbo, Zhang Wei, and Lu Jun from the affiliated Thoracic Hospital of Shanghai Jiao Tong University School of Medicine to engage in discussions on hot topics at the conference and important clinical research.
Voice of China: Research Results Presented by the Respiratory Department of Shanghai Thoracic Hospital at WCLC 2023
The team from Respiratory Department of Shanghai Thoracic Hospital had multiple research projects included in WCLC 2023, presented in various forms such as oral presentations, posters, and electronic posters. Their research spanned from Phase I clinical studies to Phase III clinical studies, covering topics from targeted therapy to immunotherapy, progressing from fundamental research to translational research, and ranging from small cell lung cancer to non-small cell lung cancer. The experts shared their research findings presented at the WCLC conference, and Dr. Han Baohui provided commentary on the key findings and clinical significance of these studies.
Dr. Zhang Wei presented research abstract EP13.01-01, which focusing on exploring the survival benefits of postoperative radiotherapy in patients with postoperative complex small cell lung cancer stratified by pN staging.
Dr. Lu Jun presented three research findings. The first was related to the combination of trametinib and anlotinib for the inhibition of MEK/RTKs pathways in KRAS-mutated non-small cell lung cancer (NSCLC) (abstract P1.02-02) . The second dealt with the genetic characteristics of TP53-mutated NSCLC patients’ metastasis (abstract EP06.03-01). The last research topic was “PEG2000-PLA Nanopolymer Micelles Reducing Paclitaxel-Associated Toxicity” (abstract EP02.01-12).
Dr. Zhong Runbo introduced a study evaluating the use of the PD-1 inhibitor sintilimab in combination with anlotinib and chemotherapy as second-line or later-line treatment for extensive-stage small cell lung cancer (abstract EP13.07-10).
Dr. Han Baohui conducted an analysis of two additional studies from the Respiratory Department of Shanghai Thoracic Hospital. The SUNRISE study compared the efficacy and safety of sintilimab in combination with anlotinib to platinum-based chemotherapy as first-line treatment for metastatic NSCLC (abstract EP11.02-03). Another study centerd on “Anti-angiogenic Therapy versus Immunotherapy: A Multicenter Study in Patients with EGFR/HER2 Exon 20 Insertion Mutant Advanced NSCLC” (abstract EP11.03-19).
Dr. Han Baohui’s Team
